CN112205684A - Smoking cessation device - Google Patents
Smoking cessation device Download PDFInfo
- Publication number
- CN112205684A CN112205684A CN202010630192.XA CN202010630192A CN112205684A CN 112205684 A CN112205684 A CN 112205684A CN 202010630192 A CN202010630192 A CN 202010630192A CN 112205684 A CN112205684 A CN 112205684A
- Authority
- CN
- China
- Prior art keywords
- tobacco
- smoking
- smoking cessation
- cigarette holder
- pipe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000005586 smoking cessation Effects 0.000 title claims abstract description 46
- 241000208125 Nicotiana Species 0.000 claims abstract description 46
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims abstract description 46
- 230000000391 smoking effect Effects 0.000 claims abstract description 37
- 235000019504 cigarettes Nutrition 0.000 claims abstract description 24
- 239000000779 smoke Substances 0.000 claims abstract description 9
- 239000000945 filler Substances 0.000 claims description 12
- 238000007789 sealing Methods 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 6
- 239000011800 void material Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 25
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract description 22
- 229960002715 nicotine Drugs 0.000 abstract description 22
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract description 22
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003571 electronic cigarette Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000467 autonomic pathway Anatomy 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002670 nicotine replacement therapy Methods 0.000 description 2
- 229960001158 nortriptyline Drugs 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- IKBZAUYPBWFMDI-UHFFFAOYSA-N 5-bromo-4-methoxy-7-methyl-2,3-dihydro-1h-indene Chemical compound C1=C(Br)C(OC)=C2CCCC2=C1C IKBZAUYPBWFMDI-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960004367 bupropion hydrochloride Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 208000028329 epileptic seizure Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 229960004751 varenicline Drugs 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- TWYFGYXQSYOKLK-CYUSMAIQSA-N varenicline tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 TWYFGYXQSYOKLK-CYUSMAIQSA-N 0.000 description 1
- 229960003977 varenicline tartrate Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F47/00—Smokers' requisites not otherwise provided for
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F1/00—Tobacco pipes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F7/00—Mouthpieces for pipes; Mouthpieces for cigar or cigarette holders
- A24F7/02—Mouthpieces for pipes; Mouthpieces for cigar or cigarette holders with detachable connecting members
Abstract
A smoking stopping device comprises tobacco pipe, tobacco rod and cigarette holder. Because the one-way variable smoke cavity is arranged, the smoking cessation process is natural and smooth. The tobacco burns fully, and the smoking satisfaction is better than the traditional cigarette. The nicotine intake is greatly reduced while the traditional smoking state is not changed, and the threshold value of smoking satisfaction is gradually reduced until the threshold value is zero.
Description
Technical Field
The invention relates to a smoking cessation device.
Background
Although not accepted by smokers, smoking carcinogenesis has been recognized worldwide. Epidemiological investigations have shown that smoking is one of the important causative factors of lung cancer, particularly squamous cell carcinoma and small-cell undifferentiated carcinoma. Smokers are 13 times more likely to suffer from lung cancer than non-smokers. Many studies suggest that smoking is a major risk factor for many cardiovascular and cerebrovascular diseases, and the incidence of coronary heart disease, hypertension, cerebrovascular diseases and peripheral vascular diseases of smokers is obviously increased. Statistics show that 75% of patients with coronary heart disease and hypertension have a history of smoking. Smoking is one of the major causes of chronic bronchitis, emphysema, and chronic airway obstruction. Experimental research shows that long-term smoking can damage and shorten cilia of bronchial mucosa and influence the cilia clearing function. Smoking can cause gastric acid secretion increase, generally 91.5% higher than that of smokers, and can inhibit the secretion of sodium bicarbonate by pancreas, so as to increase acid load of duodenum and induce ulcer. Nicotine in tobacco can reduce pyloric sphincter tone, and bile can easily flow back, thereby weakening digestive function. Smoking by women can cause menstrual disorder, difficulty in conception, ectopic pregnancy, low estrogen, osteoporosis and premature menopause. Smoking by pregnant women is prone to spontaneous abortion, fetal development retardation and low body weight of the newborn. Particularly, the following matters are: smokers must quit smoking.
Therefore, the intention smoking cessation method, the non-object smoking cessation method such as the transfer smoking cessation method, the alternative smoking cessation method and the simulated smoking cessation method, and the object smoking cessation method such as the medicine smoking cessation method, the electronic smoking cessation method and the like are available, and the method is not only suitable for people with the intention smoking cessation.
For the willingness to stop smoking, it is only applicable to a few people with strong willingness. Most smokers apparently do not apply this method; the so-called transfer smoking cessation method, substitution smoking cessation method, simulated smoking cessation method, medicine smoking cessation method, even the invention and the like are the servers of the public.
Smoking should be given up. However, from a biological point of view, any change to the physicochemical environment of a cell is a kind of mutagenesis to the cell itself; in the extreme, it is a carcinogenic factor. Mutagenesis of tissue cells by smoking is long-term for carcinogens alone, while sudden cessation of smoking can be fatal. Therefore, smokers do not quit smoking.
It is known that nicotine, when inhaled into the human body, stimulates the pituitary gland to secrete a hormone, which accelerates the heartbeat, increases the blood pressure, promotes the blood circulation of coronary vessels, revivifies the mind, enhances the responsiveness, stimulates the mental activities and enhances the memory when encountered by heart muscle cells. However, nicotine stimulates autonomic nerves, so that respiratory function is reduced, oxygen consumption of heart is increased, carbon monoxide in smoke deprives a large amount of hemoglobin, and oxygen transportation of blood is affected. In addition, nicotine can cause the surface of limbs of a person to contract, directly or indirectly increase blood pressure and pulse frequency, thereby affecting the heart, blood vessels, digestive organs and the stomach. After the nicotine is inhaled by smokers, the nicotine enters pulmonary circulation from alveoli, enters arterial circulation through left ventricle and then enters brain. Nicotine has strong lipid affinity, and can be accumulated in brain lipid, but has short action time and can be absorbed by human organs such as lung. Nicotine acts on the peripheral and central nervous systems of humans, and the autonomic nerve is stimulated to cause an increase in the number of heart beats, an increase in blood pressure, and the like. The action on the central nerve can correspondingly play a role in excitation and sedation on the spirit according to the state of the person at that time. The stimulation of small amount of nicotine increases the consciousness degree of cerebral cortex and stimulates the mood. On the other hand, when the nicotine is absorbed to a certain extent by the human body, the activity of the autonomic sympathetic nervous system is lowered, and thus the stress and uneasiness are alleviated. Nicotine contained in tobacco smoke is recognized to have both psychostimulant and sedative effects. That is, smoking can play a role in eliminating this emotion when scorched or stressed; while when people are sleepy or have slow brain reaction, smoking can make the brain clear. These two effects are referred to as "biphasic effects". This effect of nicotine can be used to modulate mental states. In daily life, people also have the experience that smoking can eliminate stress and change moods. This is why hundreds of millions of people feel like tobacco in person, though it is not a true evidence of all the physical data, but it is one of the most important reasons. For people who have no effect on quitting smoking, smoking has no substitute.
Thus, the effectiveness of non-substance smoking cessation methods such as transfer smoking cessation, substitution smoking cessation, and simulated smoking cessation is greatly compromised. Hereinafter, only the physical smoking cessation methods such as a drug smoking cessation method, an electronic smoking cessation method, and the like will be described.
The so-called drug smoking cessation method is a method of increasing the success rate of smoking cessation by reducing the symptoms of withdrawal by drug therapy. Nicotine replacement therapy (patches, gums, nasal sprays, inhalants and sublingual tablets), sustained release bupropion hydrochloride, Varenicline tartrate (Varenicline) tablets and the like are commonly used, and are also first-line drugs recommended in the smoking cessation guide of various countries. There are two more smoking cessation drugs that have proven effective: nortriptyline (tricyclic antidepressants) and clonidine (central alpha-receptor agonists), but none have passed relevant approval as first-line smoking cessation drugs. The therapeutic principle of nicotine replacement therapy is to provide part of the original nicotine obtained from tobacco in a non-tobacco form, while the therapeutic amount of nicotine is much lower than that obtained from tobacco. Not only can relieve the withdrawal symptoms and improve the smoking cessation success rate, but also can avoid the harm of harmful substances generated by smoking to the body. Clinical research proves that the treatment can control smoking addiction and relieve withdrawal symptoms, and the smoking cessation success rate is 2 times of that of placebo. However, nortriptyline and clonidine have potential cardiovascular adverse effects, and therefore, for smokers with cardiovascular disease, the use of both drugs should be avoided. Bupropion is an antidepressant with dopamine and noradrenaline, and has the side effects of dry mouth, irritability, insomnia, headache and dizziness. Can lower epileptic seizure threshold, so it is contraindicated for epileptic patients. Vanillan tartrate is a selective nicotinic acetylcholine receptor partial agonist and is useful for the reduction of smoking addiction and withdrawal symptoms. Its antagonism can in turn reduce the satisfaction of smoking during the treatment period, thereby reducing the possibility of relapse. The side effects include insomnia, nausea, flatulence, constipation, etc. And despite the lack of effectiveness of such treatments and smoking satisfaction, these side effects and potential mutagens alone are sufficient to discourage a wide range of smokers.
The electronic smoking cessation method is to heat electronic cigarette liquid (a mixed liquid of nicotine, glycerol, 1, 2-propylene glycol, polyethylene glycol and tobacco essence) by an electronic heating device to volatilize fog (containing nicotine) like a cigarette for a smoker to smoke, thereby reducing the withdrawal symptoms and increasing the success rate of smoking cessation. However, the safety of the electronic cigarette has not been fully scientifically demonstrated. Experiments show that when people use the electronic cigarette, besides nicotine, other various undiscovered toxic compounds can be inhaled into the body. Meanwhile, the electronic cigarette can release inhalable liquid fine particles, ultrafine particles, nicotine and carcinogenic substances into a room. Moreover, since the electronic cigarette device is heated at a too high temperature, a highly toxic molecule called acrolein is also generated in the process. After research and analysis, the electronic cigarette is also found to contain a large amount of propylene glycol, and the substance can cause irritation to the respiratory tract and further cause some acute symptoms. Besides nicotine, which is a harmful substance of conventional tobacco, electronic cigarettes generate substances with direct toxicity by toxic chemical fuels. Furthermore, some manufacturers add excess nicotine and even the cannabinoids Tetrahydrocannabinol (THC) to the e-liquid in order to increase satisfaction. This is already beyond the normal smoking range. Thus, there is a strong indication by experts that e-cigarettes may be more harmful to human health than traditional cigarettes.
Finally, it is worth mentioning that it has been found in practice that sufficient pure tobacco (rather than a mixture of tobacco and semi-burned tobacco) is combusted to produce smoke which is essential to improve the so-called smoking satisfaction. Two flavors of chewing wax are usually the common knowledge of smokers.
Disclosure of Invention
In order to overcome various defects of the existing smoking cessation device and method, the invention provides the smoking cessation device which is provided with the one-way variable smoking cavity and has the same structure as the traditional cigarette, so that natural smoking and safe smoking cessation can be shared.
The technical scheme adopted by the invention for solving the technical problems is as follows: the invention relates to a smoking cessation device, which consists of a tobacco pipe, a tobacco rod and a cigarette holder, and is characterized in that: pipe, tobacco rod, cigarette holder physical connection in proper order, the pipe comprises the pipe body, filler block, swivel ring, tobacco cavity and sealing washer, its characterized in that: the tobacco pipe body is the supporting body of filler block, swivel ring, tobacco cavity and sealing washer, the tobacco cavity is the space that tobacco pipe body and filler block enclose, the space size in tobacco cavity can be by controlling swivel ring operation the filler block and change, the cigarette holder comprises cigarette holder body, sealing washer and filter core, its characterized in that: the cigarette holder body, the sealing ring and the filter element are physically connected.
The smoking cessation cigarette holder has the beneficial effects that the smoking cessation process is natural and smooth due to the arrangement of the one-way variable cigarette cavity. The tobacco burns fully, and the smoking satisfaction is better than the traditional cigarette. The nicotine intake is greatly reduced while the traditional smoking state is not changed, and the threshold value of smoking satisfaction is gradually reduced until the threshold value is zero.
Drawings
The invention is further illustrated with reference to the following figures and examples.
FIG. 1 is a schematic structural diagram of one embodiment of the present invention.
In the embodiment shown in the drawings, the smoking cessation device of the embodiment comprises a tobacco pipe 100, a tobacco rod 200 and a cigarette holder 300, and is characterized in that: the pipe 100, the tobacco rod 200, the cigarette holder 300 are connected physically in proper order, the pipe 100 comprises the pipe body 110, the filler block 120, the rotary ring 130, the tobacco cavity 150 and the sealing ring 140, and is characterized in that: the tobacco pipe body 110 is a carrier of the filler block 120, the rotary ring 130, the tobacco cavity 150 and the sealing ring 140, the tobacco cavity 150 is a space enclosed by the tobacco pipe body 110 and the filler block 120, the size of the tobacco cavity 150 can be changed by operating the filler block 120 with the rotary ring 130, the mouthpiece 300 is composed of a mouthpiece body 310, a sealing ring 330 and a filter element 320, and is characterized in that: the mouthpiece body 310, the sealing ring 330 and the filter element 320 are physically connected. .
Thus, the smoking cessation device of the present embodiment has a structure identical to that of a conventional cigarette after the tobacco is loaded in the tobacco chamber 150, and thus, a user will not feel uncomfortable during use.
Preferably, the inner wall of the cigarette holder body is provided with threads.
Preferably, the inner wall of the tobacco rod is arranged to be curved.
Preferably, the knob operates the pad to change either by changing the clear height of the smoke chamber or by changing the void diameter of the smoke chamber.
Preferably, the thread is arranged to rotate left or right.
Preferably, the rotary ring and the tobacco pipe body are concentric and have approximately the same diameter.
Claims (6)
1. The utility model provides a device of quiing smoking, comprises pipe, tobacco rod and cigarette holder, its characterized in that: pipe, tobacco rod, cigarette holder physical connection in proper order, the pipe comprises the pipe body, filler block, swivel ring, tobacco cavity and sealing washer, its characterized in that: the tobacco pipe body is the supporting body of filler block, swivel ring, tobacco cavity and sealing washer, the tobacco cavity is the space that tobacco pipe body and filler block enclose, the space size in tobacco cavity can be by controlling the knob operation the filler block and change, the cigarette holder comprises cigarette holder body, sealing washer and filter core, its characterized in that: the cigarette holder body, the sealing ring and the filter element are physically connected.
2. A smoking cessation device as claimed in claim 1 wherein: the inner wall of the cigarette holder body is provided with threads.
3. A smoking cessation device as claimed in claim 1 wherein: the inner wall of the cigarette rod is arranged to be curved surface shape.
4. A smoking cessation device as claimed in claim 1 wherein: the swivel operates the pad to change either by changing the clear height of the smoke chamber or by changing the void diameter of the smoke chamber.
5. A smoking cessation device as claimed in claim 2 wherein: the thread is configured to be left-handed or right-handed.
6. A smoking cessation device as claimed in claim 1 wherein: the rotary ring and the tobacco pipe body are concentric and have approximately the same diameter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010630192.XA CN112205684A (en) | 2020-06-26 | 2020-06-26 | Smoking cessation device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010630192.XA CN112205684A (en) | 2020-06-26 | 2020-06-26 | Smoking cessation device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112205684A true CN112205684A (en) | 2021-01-12 |
Family
ID=74059368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010630192.XA Pending CN112205684A (en) | 2020-06-26 | 2020-06-26 | Smoking cessation device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112205684A (en) |
-
2020
- 2020-06-26 CN CN202010630192.XA patent/CN112205684A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Flaten et al. | Caffeine-associated stimuli elicit conditioned responses: an experimental model of the placebo effect | |
| Lucchesi et al. | The role of nicotine as a determinant of cigarette smoking frequency in man with observations of certain cardiovascular effects associated with the tobacco alkaloid | |
| Sullivan et al. | Primary role of respiratory afferents in sustaining breathing rhythm | |
| Westman et al. | Dissociating the nicotine and airway sensory effects of smoking | |
| EP1304048B1 (en) | Composition to reduce or quit smoking addiction | |
| DK173353B1 (en) | Capsule comprising a nicotine-containing liquid medium for oral ingestion | |
| WO2006097447A1 (en) | Combined use of herbal cigarettes and nicotine replacement therapy | |
| Behm et al. | Reducing craving for cigarettes while decreasing smoke intake using capsaicin-enhanced low tar cigarettes. | |
| Moreno-Coutino et al. | Long-term changes in sleep and depressive symptoms of smokers in abstinence | |
| JPH11215977A (en) | Coffee cigarette | |
| Kou et al. | Reflex changes in breathing pattern evoked by inhalation of wood smoke in rats | |
| Dixon | The tobacco habit | |
| CN112205684A (en) | Smoking cessation device | |
| US9061052B2 (en) | Aqueous extract of tobacco leaves, its uses in the treatment of dependence | |
| Hartiala et al. | Cigarette smoke-induced bronchoconstriction in dogs: vagal and extravagal mechanisms | |
| Hillis et al. | Effect of hexamethonium iodide on lobeline-stimulated coughing | |
| Sudano et al. | Smoking, smoking cessation and cardiovascular risk | |
| Hybbinette | A pharmacological evaluation of the short-term effect of cigarette smoke on mucociliary activity | |
| JPH11127834A (en) | Coffee cigarette and metal oxide filter | |
| Aswad | Effect Of Slow Deep Breathing And Aromathera-Py Of Lavender (Lavandula Angustifolia) On Blood Pressure In Hypertension Patients In Panti Werdha Ilomata Of Gorontalo City | |
| Lee et al. | Hexamethonium aerosol prevents pulmonary reflexes induced by cigarette smoke in dogs | |
| Jones | Cigarettes, respiratory rate, and the relaxation paradox | |
| RU2428163C2 (en) | Method of treating tobacco addiction in women | |
| Dixon | THE TWELFTH NORMAN KERR MEMORIAL LECTURE: 1927.* THE TOBACCO HABIT | |
| Chervinskaya | Respiratory hygiene with the dry sodium chloride aerosol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210112 |